New treatments in Alzheimer's disease

Affiliations

¹ Neurology and Molecular Neuroscience, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK.
² Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, CF14 4XW, UK. robertsonnp@cardiff.ac.uk.

Comment

William O Pickrell et al. J Neurol. 2018 Sep.

. 2018 Sep;265(9):2162-2163.

doi: 10.1007/s00415-018-9018-1.

¹ Neurology and Molecular Neuroscience, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK.
² Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, CF14 4XW, UK. robertsonnp@cardiff.ac.uk.

No abstract available

Comment on

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. Soininen H, et al. Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0. Epub 2017 Oct 30. Lancet Neurol. 2017. PMID: 29097166 Free PMC article. Clinical Trial.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Honig LS, et al. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971. N Engl J Med. 2018. PMID: 29365294 Clinical Trial.
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Egan MF, et al. N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441. N Engl J Med. 2018. PMID: 29719179 Free PMC article. Clinical Trial.